www.sbdmj.com - Stomatologija - Baltic Dental and Maxillofacial Journal

Stomatologija 2019; 21 (1): 13-7 237 KB

A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw

Daiga Auzina^{1, 2}, Anda Slaidina^{1, 3}, Marina Sevastjanova^{1, 3}, Renars Erts⁴, Aivars Lejnieks¹, Sandra Lejniece^{1, 2}

Summary

Objective. Medication-related osteonecrosis of the jaw (MRONJ) is a rare complication of antiresorptive or antiangiogenetic therapy that manifests as an exposed bone with clinical signs of infection, persisting for more than 8 weeks, without history of radiation therapy or metastases to the jaws. The aim of the study was to describe the incidence, risk factors, staging process and clinical course of MRONJ in patients with multiple myeloma (MM).

Materials and methods. We retrospectively analyzed all (126) newly diagnosed MM patients at Riga East Clinical University Hospital (Riga. Latvia) from June 2014 to June 2017.

Results. Among 88 MM patients treated with bisphosphonates (BP), 6 (6.8%) patients developed MRONJ. All six patients received intravenous nitrogen-containing BPs. The average time until MRONJ manifestation was under two years. For our patients the severity of MRONJ was stage I in two, stage II in three, and stage III in one patient. Five patients had MRONJ of mandibula and one of maxilla. All patients with MRONJ had undergone a dental extraction or a trauma before the development of MRONJ.

Conclusion. We found that MRONJ correlated with the patient’s age. The average time until MRONJ manifestation in reserach group is 2 years. One of triggerring MRONJ factors are tooth extraction or trauma.

Key words: medication-related osteonecrosis of the jaw, bisphosphonates, multiple myeloma, osteonecrosis.

Received: 18 05 2018

Accepted for publishing: 20 03 2019

¹Rīga Stradiņš University. Riga. Latvia

²Riga East Clinical University Hospital. Riga. Latvia

³Riga Stradiņš University Institute of Stomatology. Riga. Latvia

⁴University of Latvia. Faculty of medicine. Riga. Latvia

Address correspondence to Daiga Auzina. Faculty of medicine. University of Latvia, 4 Hipokrata Street. Riga. Latvia.

E-mail address: daiga.auzina@aslimnica.lv



	Baltic Dental and Maxillofacial Journal

March, 2019, Vol. 21, No. 1 CONTENTS REVIEWS Diagnostic methods and treatment strategies of impacted maxillary canines: A literature review Viktorija Grybienė, Donata Juozėnaitė, Kristina Kubiliūtė 3-12 SCIENTIFIC ARTICLES A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw Daiga Auzina, Anda Slaidina, Marina Sevastjanova, Renars Erts, Aivars Lejnieks, Sandra Lejniece 13-17 Comparison of pressure pain threshold between muscles in the contracted and relaxed state in patients with myofascial pain: a cross-sectional study Rodrigo Lorenzi Poluha, Matheus Cavassani Pereira, Rafael Dos Santos Silva 18-21 REVIEWS Types of root resorptions related to orthodontic treatment Giedrė Ruškytė, Donata Juozėnaitė, Kristina Kubiliūtė 22-27 SCIENTIFIC ARTICLES Orthodontic treatment complexity, outcome and need among school age patients of Lithuanian university of health sciences clinic of orthodontics Rokas Liausas, Zygimantas Labanauskas, Vilma Svalkauskiene, Dalia Smailiene, Justina Vaiciuniene 28-32 © 2019 Stomatologija		Stomatologija 2019; 21 (1): 13-7 237 KB A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw Daiga Auzina^{1, 2}, Anda Slaidina^{1, 3}, Marina Sevastjanova^{1, 3}, Renars Erts⁴, Aivars Lejnieks¹, Sandra Lejniece^{1, 2} Summary Objective. Medication-related osteonecrosis of the jaw (MRONJ) is a rare complication of antiresorptive or antiangiogenetic therapy that manifests as an exposed bone with clinical signs of infection, persisting for more than 8 weeks, without history of radiation therapy or metastases to the jaws. The aim of the study was to describe the incidence, risk factors, staging process and clinical course of MRONJ in patients with multiple myeloma (MM). Materials and methods. We retrospectively analyzed all (126) newly diagnosed MM patients at Riga East Clinical University Hospital (Riga. Latvia) from June 2014 to June 2017. Results. Among 88 MM patients treated with bisphosphonates (BP), 6 (6.8%) patients developed MRONJ. All six patients received intravenous nitrogen-containing BPs. The average time until MRONJ manifestation was under two years. For our patients the severity of MRONJ was stage I in two, stage II in three, and stage III in one patient. Five patients had MRONJ of mandibula and one of maxilla. All patients with MRONJ had undergone a dental extraction or a trauma before the development of MRONJ. Conclusion. We found that MRONJ correlated with the patient’s age. The average time until MRONJ manifestation in reserach group is 2 years. One of triggerring MRONJ factors are tooth extraction or trauma. Key words: medication-related osteonecrosis of the jaw, bisphosphonates, multiple myeloma, osteonecrosis. Received: 18 05 2018 Accepted for publishing: 20 03 2019 ¹Rīga Stradiņš University. Riga. Latvia ²Riga East Clinical University Hospital. Riga. Latvia ³Riga Stradiņš University Institute of Stomatology. Riga. Latvia ⁴University of Latvia. Faculty of medicine. Riga. Latvia Address correspondence to Daiga Auzina. Faculty of medicine. University of Latvia, 4 Hipokrata Street. Riga. Latvia. E-mail address: daiga.auzina@aslimnica.lv